Mark J. Macielag

3.6k total citations · 1 hit paper
74 papers, 2.5k citations indexed

About

Mark J. Macielag is a scholar working on Molecular Biology, Pharmacology and Organic Chemistry. According to data from OpenAlex, Mark J. Macielag has authored 74 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 25 papers in Pharmacology and 21 papers in Organic Chemistry. Recurrent topics in Mark J. Macielag's work include Antimicrobial Resistance in Staphylococcus (15 papers), Cancer therapeutics and mechanisms (13 papers) and Antibiotic Resistance in Bacteria (12 papers). Mark J. Macielag is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (15 papers), Cancer therapeutics and mechanisms (13 papers) and Antibiotic Resistance in Bacteria (12 papers). Mark J. Macielag collaborates with scholars based in United States, Belgium and Russia. Mark J. Macielag's co-authors include Karen Bush, Darren Abbanat, David C. Hooper, Chi Hye Park, Ari Robicsek, George A. Jacoby, Jacob Strahilevitz, Barbara D. Foleno, Michele A. Weidner‐Wells and Raúl Goldschmidt and has published in prestigious journals such as Journal of the American Chemical Society, Nature Medicine and Diabetes.

In The Last Decade

Mark J. Macielag

72 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase

2005 750 citations Ari Robicsek, Jacob Strahilevitz et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark J. Macielag United States	25	895	884	785	552	346	74	2.5k
Peter J. Petersen United States	35	1.7k 1.8×	1.3k 1.5×	675 0.9×	1.3k 2.4×	745 2.2×	74	3.6k
Shutao Ma China	25	555 0.6×	963 1.1×	800 1.0×	283 0.5×	278 0.8×	105	2.1k
David E. Ehmann United States	22	1.1k 1.3×	994 1.1×	270 0.3×	1.0k 1.8×	190 0.5×	29	2.2k
Ana Martins Portugal	29	583 0.7×	1.1k 1.2×	325 0.4×	328 0.6×	308 0.9×	80	2.4k
Nathaniel I. Martin Netherlands	35	621 0.7×	2.0k 2.3×	536 0.7×	548 1.0×	286 0.8×	135	3.4k
John P. O’Donnell United States	20	701 0.8×	682 0.8×	493 0.6×	588 1.1×	121 0.3×	51	2.4k
Sushmita D. Lahiri United States	28	1.1k 1.2×	1.0k 1.2×	234 0.3×	700 1.3×	281 0.8×	41	2.3k
Robert W. Huigens United States	31	353 0.4×	1.4k 1.6×	1.1k 1.3×	331 0.6×	286 0.8×	63	2.5k
Abdallah Mahamoud France	15	525 0.6×	493 0.6×	363 0.5×	234 0.4×	119 0.3×	34	1.2k
Inshad Ali Khan India	32	541 0.6×	1.4k 1.6×	789 1.0×	519 0.9×	698 2.0×	97	3.1k

Countries citing papers authored by Mark J. Macielag

Since Specialization

Citations

This map shows the geographic impact of Mark J. Macielag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Macielag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Macielag more than expected).

Fields of papers citing papers by Mark J. Macielag

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Macielag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Macielag. The network helps show where Mark J. Macielag may publish in the future.

Co-authorship network of co-authors of Mark J. Macielag

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Macielag. A scholar is included among the top collaborators of Mark J. Macielag based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Macielag. Mark J. Macielag is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patch, Raymond J., Rui Zhang, Suzanne C. Edavettal, et al.. (2022). Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists. European Journal of Medicinal Chemistry. 236. 114330–114330. 5 indexed citations

Zhu, Bin, Peter J. Connolly, Sui‐Po Zhang, et al.. (2020). The discovery of diazetidinyl diamides as potent and reversible inhibitors of monoacylglycerol lipase (MAGL). Bioorganic & Medicinal Chemistry Letters. 30(12). 127198–127198. 7 indexed citations

Zhu, Bin, Jay M. Matthews, Mingde Xia, et al.. (2016). Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists. Bioorganic & Medicinal Chemistry Letters. 26(22). 5597–5601. 5 indexed citations

Matthews, Jay M., James J. McNally, Peter J. Connolly, et al.. (2016). Tetrahydroindazole derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists. Bioorganic & Medicinal Chemistry Letters. 26(21). 5346–5349. 15 indexed citations

Macielag, Mark J.. (2008). How Can We Improve our Anti-Infective Compound Libraries?. 46th Annual Meeting. 1 indexed citations

Baum, Ellen Z., Steven M. Crespo‐Carbone, Alexandra L. Klinger, et al.. (2007). A MurF Inhibitor That Disrupts Cell Wall Biosynthesis in Escherichia coli. Antimicrobial Agents and Chemotherapy. 51(12). 4420–4426. 37 indexed citations

Zhu, Bin, et al.. (2007). Synthesis and antibacterial activity of 3-keto-6-O-carbamoyl-11,12-cyclic thiocarbamate erythromycin A derivatives. Bioorganic & Medicinal Chemistry Letters. 17(14). 3900–3904. 28 indexed citations

Ashley, Gary W., Mark A. Burlingame, Ruchir P. Desai, et al.. (2006). Preparation of Erythromycin Analogs Having Functional Groups at C-15. The Journal of Antibiotics. 59(7). 392–401. 19 indexed citations

Grant, Eugene B., et al.. (2006). Synthesis and antibacterial activity of 6-O-heteroarylcarbamoyl-11,12-lactoketolides. Bioorganic & Medicinal Chemistry Letters. 16(7). 1929–1933. 10 indexed citations

10.

Robicsek, Ari, Jacob Strahilevitz, George A. Jacoby, et al.. (2005). Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nature Medicine. 12(1). 83–88. 750 indexed citations breakdown →

11.

Shaw, Simon J., Darren Abbanat, Gary W. Ashley, et al.. (2005). 15-Amido Erythromycins: Synthesis and in Vitro Activity of a New Class of Macrolide Antibiotics. The Journal of Antibiotics. 58(3). 167–177. 14 indexed citations

12.

Bush, Karen, Mark J. Macielag, & Michele A. Weidner‐Wells. (2004). Taking inventory: antibacterial agents currently at or beyond Phase 1. Current Opinion in Microbiology. 7(5). 466–476. 87 indexed citations

13.

Weidner‐Wells, Michele A., Harvey M. Werblood, Raúl Goldschmidt, et al.. (2004). The synthesis and antimicrobial evaluation of a new series of isoxazolinyl oxazolidinones. Bioorganic & Medicinal Chemistry Letters. 14(12). 3069–3072. 22 indexed citations

14.

Foleno, Barbara D., Raúl Goldschmidt, Dennis J. Hlasta, et al.. (2003). Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones. Bioorganic & Medicinal Chemistry Letters. 13(23). 4173–4177. 37 indexed citations

15.

Sui, Zhihua, Mark J. Macielag, Weiqin Jiang, et al.. (2003). Synthesis and biological activities of novel β-Carbolines as PDE5 inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(4). 761–765. 12 indexed citations

16.

Weidner‐Wells, Michele A., Kwasi A. Ohemeng, Van N. Nguyen, et al.. (2001). Amidino benzimidazole inhibitors of bacterial two-component systems. Bioorganic & Medicinal Chemistry Letters. 11(12). 1545–1548. 111 indexed citations

17.

Macielag, Mark J., Theo Peeters, & Inge Depoortere. (1994). Synthesis and characterization of site‐specific biotinylated probes for the motilin receptor*. International journal of peptide & protein research. 44(6). 582–588. 2 indexed citations

18.

Macielag, Mark J., Theo Peeters, Zenon Konteatis, et al.. (1992). Synthesis and in vitro evaluation of [Leu13]porcine motilin fragments. Peptides. 13(3). 565–569. 37 indexed citations

19.

Peeters, Theo, Mark J. Macielag, Inge Depoortere, et al.. (1992). d-Amino acid and alanine scans of the bioactive portion of porcine motilin. Peptides. 13(6). 1103–1107. 47 indexed citations

20.

Florance, James R., Zenon Konteatis, Mark J. Macielag, Ralph A. Lessor, & Alphonse Galdes. (1991). Capillary zone electrophoresis studies of motilin peptides. Journal of Chromatography A. 559(1-2). 391–399. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact